| Mtb group (n = 22) | Non-Mtb group (n = 52) | pvalue |
---|---|---|---|
Age ≥ 65 years | 9 (41%) | 24 (46%) | 0.678 |
Male gender | 16 (73%) | 43 (83%) | 0.330 |
*Underlying co-morbid condition | 10 (48%) | 30 (57%) | 0.334 |
Timing of smear reversion after treatment | Â | Â | Â |
   Median (range): days | 68 (16 ~ 647) | 135 (43 ~ 760) | 0.240†|
   Within 2 months | 9 (41%) | 5 (10%) | 0.002 |
   Before sputum culture conversion | 17 (77%) | 11 (20%) | < 0.001 |
*Symptoms not improved at smear reversion | 13 (59%) | 15 (29%) | 0.014 |
Regimen modification before smear reversion | 13 (59%) | 19 (37%) | 0.073 |
Receiving direct observed therapy | 9 (41%) | 41 (79%) | 0.002 |
Mortality at the end of follow-up | 7 (32%) | 8 (15%) | 0.118 |
Median survival: months | 12.8 | 11.1 | 0.178†|
Treatment failure | 6 (27%) | 5 (10%) | 0.051 |